This study evaluates the effectiveness of 68Ga-PSMA ligand PET/CT in detecting biochemical recurrence after radical prostatectomy. The research involved 248 patients, with a median PSA level of 1.99 ng/mL. The detection rates were 96.8%, 93.0%, 72.7%, and 57.9% for PSA levels of ≥2, 1 to <2, 0.5 to <1, and 0.2 to <0.5 ng/mL, respectively. Higher PSA velocity was associated with higher detection rates, but no significant association was found with PSA doubling time. 68Ga-PSMA ligand PET provided additional diagnostic information in 32.7% of patients, and in 24.6% of patients, it identified additional involved regions. The study concluded that 68Ga-PSMA ligand PET/CT has significantly higher detection rates than other imaging modalities, particularly in low PSA values (<0.5 ng/mL), which can influence clinical management.This study evaluates the effectiveness of 68Ga-PSMA ligand PET/CT in detecting biochemical recurrence after radical prostatectomy. The research involved 248 patients, with a median PSA level of 1.99 ng/mL. The detection rates were 96.8%, 93.0%, 72.7%, and 57.9% for PSA levels of ≥2, 1 to <2, 0.5 to <1, and 0.2 to <0.5 ng/mL, respectively. Higher PSA velocity was associated with higher detection rates, but no significant association was found with PSA doubling time. 68Ga-PSMA ligand PET provided additional diagnostic information in 32.7% of patients, and in 24.6% of patients, it identified additional involved regions. The study concluded that 68Ga-PSMA ligand PET/CT has significantly higher detection rates than other imaging modalities, particularly in low PSA values (<0.5 ng/mL), which can influence clinical management.